RE: GEN1079 ready to dose?18 Jun 2026 14:03
Berm .. I actually can’t find a scancell doc that refers to Genmab name or a Genmab doc that refers to the scancell name .. but thought this was interesting from scancell describing the use of SC129 ..
“”The first partnering deal, with Genmab, was struck in October 2022 and effectively validated the approach. Genmab acquired the rights to develop one of these preclinical Glymabs, SC129, into multiple therapeutic modalities for all disease areas, excluding cell therapy applications (which are retained by Scancell). The total potential milestones could reach up to a maximum of $624m across all modalities, with Genmab paying Scancell a $6m upfront fee and potential future milestones of up to $208m for each product. Scancell is also entitled to receive a low single digit royalty on net sales of all commercialised products. Genmab is a well-regarded, highly experienced, and commercially successful antibody expert.”
I guess we will have to wait for more details on GEN1079.
Take care all ..